BACKGROUND: Doublecortin-like kinase 1 (DCLK1), a putative tumor stem cell marker has been shown to be highly expressed in the stromal and epithelial compartments in colon and pancreatic cancer as well as Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). AIM: To prospectively investigate whether the immunohistochemical expression of DCLK1 was associated with detectable DCLK1 plasma expression in patients with existing BE and EAC. METHODS: Immunohistochemistry was performed on paraffin-embedded sections using DCLK1 antibody and scored based on staining intensity and tissue involvement. Purified human plasma samples were subjected to Western blot and ELISA analysis. RESULTS: Forty (40) patients were enrolled: 10 controls (normal endoscopy) and 30 with BE/EAC (13 nondysplastic BE [NDBE], 9 dysplastic BE [DBE] and 8 EAC). Mean epithelial DCLK1 staining was as follows: controls = 0.11, NDBE = 3.83, DBE = 6.0, EAC = 7.17. Mean stromal DCLK1 staining was as follows: NDBE = 5.83, DBE = 5.375, EAC = 10.83. DCLK1 was detected by plasma Western blot in 1 control and in all patients with BE/EAC p < 0.0005. Plasma DCLK1 was elevated by ELISA in EAC compared to other groups, p < 0.05. CONCLUSIONS: Increased expression of DCLK1 was observed in the epithelium, stroma and plasma of patients with BE/EAC. Furthermore, the presence of detectable DCLK1 in plasma of BE/EAC patients may provide a less invasive, detection tool in those patients as well as represent a novel molecular marker distinguishing between normal esophageal mucosa and BE or EAC.
BACKGROUND:Doublecortin-like kinase 1 (DCLK1), a putative tumor stem cell marker has been shown to be highly expressed in the stromal and epithelial compartments in colon and pancreatic cancer as well as Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). AIM: To prospectively investigate whether the immunohistochemical expression of DCLK1 was associated with detectable DCLK1 plasma expression in patients with existing BE and EAC. METHODS: Immunohistochemistry was performed on paraffin-embedded sections using DCLK1 antibody and scored based on staining intensity and tissue involvement. Purified human plasma samples were subjected to Western blot and ELISA analysis. RESULTS: Forty (40) patients were enrolled: 10 controls (normal endoscopy) and 30 with BE/EAC (13 nondysplastic BE [NDBE], 9 dysplastic BE [DBE] and 8 EAC). Mean epithelial DCLK1 staining was as follows: controls = 0.11, NDBE = 3.83, DBE = 6.0, EAC = 7.17. Mean stromal DCLK1 staining was as follows: NDBE = 5.83, DBE = 5.375, EAC = 10.83. DCLK1 was detected by plasma Western blot in 1 control and in all patients with BE/EAC p < 0.0005. Plasma DCLK1 was elevated by ELISA in EAC compared to other groups, p < 0.05. CONCLUSIONS: Increased expression of DCLK1 was observed in the epithelium, stroma and plasma of patients with BE/EAC. Furthermore, the presence of detectable DCLK1 in plasma of BE/EAC patients may provide a less invasive, detection tool in those patients as well as represent a novel molecular marker distinguishing between normal esophageal mucosa and BE or EAC.
Authors: Shui Ping Tu; Michael Quante; Govind Bhagat; Shigeo Takaishi; Guanglin Cui; Xiang Dong Yang; Sureshkumar Muthuplani; Wataru Shibata; James G Fox; D Mark Pritchard; Timothy C Wang Journal: Cancer Res Date: 2011-04-21 Impact factor: 12.701
Authors: Michael Quante; Govind Bhagat; Julian A Abrams; Frederic Marache; Pamela Good; Michele D Lee; Yoomi Lee; Richard Friedman; Samuel Asfaha; Zinaida Dubeykovskaya; Umar Mahmood; Jose-Luiz Figueiredo; Jan Kitajewski; Carrie Shawber; Charles J Lightdale; Anil K Rustgi; Timothy C Wang Journal: Cancer Cell Date: 2012-01-17 Impact factor: 31.743
Authors: Shivaram Bhat; Helen G Coleman; Fouad Yousef; Brian T Johnston; Damian T McManus; Anna T Gavin; Liam J Murray Journal: J Natl Cancer Inst Date: 2011-06-16 Impact factor: 13.506
Authors: Sachin Wani; Gary W Falk; Jane Post; Lisa Yerian; Matthew Hall; Amy Wang; Neil Gupta; Srinivas Gaddam; Mandeep Singh; Vikas Singh; Keng-Yu Chuang; Vikram Boolchand; Hemanth Gavini; John Kuczynski; Priti Sud; Ajay Bansal; Amit Rastogi; Sharad C Mathur; Patrick Young; Brooks Cash; John Goldblum; David A Lieberman; Richard E Sampliner; Prateek Sharma Journal: Gastroenterology Date: 2011-06-30 Impact factor: 22.682
Authors: Sripathi M Sureban; Randal May; Nathaniel Weygant; Dongfeng Qu; Parthasarathy Chandrakesan; Eddie Bannerman-Menson; Naushad Ali; Panayotis Pantazis; Christoph B Westphalen; Timothy C Wang; Courtney W Houchen Journal: Cancer Lett Date: 2014-05-28 Impact factor: 8.679
Authors: Sripathi M Sureban; Randal May; Dongfeng Qu; Nathaniel Weygant; Parthasarathy Chandrakesan; Naushad Ali; Stan A Lightfoot; Panayotis Pantazis; Chinthalapally V Rao; Russell G Postier; Courtney W Houchen Journal: PLoS One Date: 2013-09-09 Impact factor: 3.240
Authors: Cedric Roudebush; Alma Catala-Valentin; Thomas Andl; Gregoire F Le Bras; Claudia D Andl Journal: Cytokine Date: 2019-07-29 Impact factor: 3.861
Authors: Moritz Middelhoff; C Benedikt Westphalen; Yoku Hayakawa; Kelley S Yan; Michael D Gershon; Timothy C Wang; Michael Quante Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-07-06 Impact factor: 4.052
Authors: Raphael Schellnegger; Anne Quante; Susanne Rospleszcz; Martina Schernhammer; Bettina Höhl; Moritz Tobiasch; Agnieszka Pastula; Anna Brandtner; Julian A Abrams; Konstantin Strauch; Roland M Schmid; Michael Vieth; Timothy C Wang; Michael Quante Journal: Cancer Prev Res (Phila) Date: 2016-11-02
Authors: Yan Liu; Fleur M Ferguson; Lianbo Li; Miljan Kuljanin; Caitlin E Mills; Kartik Subramanian; Wayne Harshbarger; Sudershan Gondi; Jinhua Wang; Peter K Sorger; Joseph D Mancias; Nathanael S Gray; Kenneth D Westover Journal: Cell Chem Biol Date: 2020-08-04 Impact factor: 8.116